Unigestion Holding SA decreased its position in shares of Eli Lilly And Co (NYSE:LLY) by 11.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 668,553 shares of the company’s stock after selling 84,739 shares during the quarter. Eli Lilly And Co makes up approximately 1.5% of Unigestion Holding SA’s holdings, making the stock its 10th largest holding. Unigestion Holding SA’s holdings in Eli Lilly And Co were worth $71,742,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of LLY. Gyroscope Capital Management Group LLC lifted its stake in shares of Eli Lilly And Co by 0.5% in the 3rd quarter. Gyroscope Capital Management Group LLC now owns 89,849 shares of the company’s stock valued at $10,334,000 after purchasing an additional 469 shares during the period. Bbva Compass Bancshares Inc. lifted its stake in shares of Eli Lilly And Co by 5.3% in the 3rd quarter. Bbva Compass Bancshares Inc. now owns 9,349 shares of the company’s stock valued at $1,003,000 after purchasing an additional 474 shares during the period. Pure Financial Advisors Inc. lifted its stake in shares of Eli Lilly And Co by 18.3% in the 3rd quarter. Pure Financial Advisors Inc. now owns 3,166 shares of the company’s stock valued at $340,000 after purchasing an additional 490 shares during the period. Balasa Dinverno & Foltz LLC lifted its stake in shares of Eli Lilly And Co by 15.9% in the 3rd quarter. Balasa Dinverno & Foltz LLC now owns 3,629 shares of the company’s stock valued at $389,000 after purchasing an additional 499 shares during the period. Finally, Legacy Private Trust Co. lifted its stake in shares of Eli Lilly And Co by 5.2% in the 3rd quarter. Legacy Private Trust Co. now owns 10,365 shares of the company’s stock valued at $1,112,000 after purchasing an additional 508 shares during the period. 76.17% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have recently weighed in on LLY shares. Wolfe Research started coverage on Eli Lilly And Co in a research note on Tuesday, October 23rd. They issued a “market perform” rating and a $119.00 price target on the stock. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b+” rating in a research note on Tuesday. Goldman Sachs Group set a $100.00 price target on Eli Lilly And Co and gave the company a “neutral” rating in a research note on Wednesday, July 25th. Credit Suisse Group increased their price target on Eli Lilly And Co from $84.00 to $86.00 and gave the company an “underperform” rating in a research note on Wednesday, July 25th. Finally, BMO Capital Markets upgraded shares of Eli Lilly And Co from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $107.00 to $130.00 in a research report on Thursday, October 4th. Nine analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $111.19.

LLY opened at $112.21 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.09. Eli Lilly And Co has a 12 month low of $73.69 and a 12 month high of $116.61. The firm has a market capitalization of $116.23 billion, a P/E ratio of 26.22, a PEG ratio of 1.75 and a beta of 0.29.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, beating the Zacks’ consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The business had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the prior year, the company earned $1.05 EPS. The firm’s quarterly revenue was up 7.1% on a year-over-year basis. As a group, sell-side analysts forecast that Eli Lilly And Co will post 5.57 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.01%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 174,696 shares of the stock in a transaction dated Wednesday, October 17th. The stock was sold at an average price of $113.25, for a total transaction of $19,784,322.00. Following the completion of the transaction, the insider now owns 119,005,804 shares in the company, valued at approximately $13,477,407,303. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Eli & Co Lilly sold 700,000 shares of the stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $14.00, for a total value of $9,800,000.00. Following the transaction, the insider now owns 3,148,647 shares of the company’s stock, valued at approximately $44,081,058. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,881,684 shares of company stock valued at $133,274,076. 0.11% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Eli Lilly And Co (LLY) Holdings Cut by Unigestion Holding SA” was posted by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2018/11/10/eli-lilly-and-co-lly-holdings-cut-by-unigestion-holding-sa.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: How can you know how many shares are floating?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.